Insmed recently announced that it will present four abstracts on its treprostinil palmitil inhalation powder (TPIP) program, including Phase 3 PALM-PAH study design and Phase 2b topline results in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results